Hikma Pharmaceuticals

Happy New Year from all of us at #Hikma

#LookingBack2024. We empowered our people through our culture of progress and belonging, working together, supporting each other and driving our business forward in pursuit of our shared purpose of putting better health within reach. Read more: Hikma: https://lnkd.in/eev6awqK

#LookingBack2024. Our growth is driven by our three world-class businesses: Injectables, Branded, and Generics, each of which remains crucial in ensuring patient access. The synergies between these businesses allow us to deliver both our strategy and purpose, leveraging our global expertise to improve local health outcomes. Read more here: https://lnkd.in/dWM7bTNd #Injectables #Branded #Generics #HikmaPharmaceuticals #Leadership

#LookingBack2024. We are committed to making our operations greener and to improving our environmental performance. We reduced our Scope 1 & 2 emissions by 15% (using a 2020 baseline), and made carbon reduction savings equal to 123,727 tonnes of CO2 equivalent. Read more: https://lnkd.in/escxJm5m #Hikma #Sustainability #EnergyEfficiency #CarbonReductionSavings

#LookingBack2024. #Hikma’s long-standing work with government officials, health care providers, non-profit organisations and the public health community continues helping those on the frontlines of the opioid public health emergency across the US. Read more about our efforts: https://www.hikma.com/ #US #Hikma #HealthcareProfessionals #PublicHealth

#LookingBack2024. #On 10 September, Hikma completes the acquisition of Xellia Pharmaceuticals’ US finished dosage form (FDF) business and related assets -including a commercial portfolio and pipeline of differentiated products, a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities, and an R&D centre in Zagreb, Croatia supporting the long-term growth of our Injectables business. Learn more: https://lnkd.in/gd_j7wCP #Hikma #Injectables #Sterile #Hospitals #Pharmaceuticals

Meet Nicholas Slawinski, Generalist, People, Cherry Hill, US and discover why he likes working at #Hikma! Watch the video. https://lnkd.in/dkNrxMrM Learn more https://lnkd.in/et9vgXWX

#LookingBack2024. In August, Said Darwazah, Executive Chairman was included on the prestigious Arabian Business Healthcare Visionaries list and ranked in September as second on the annual Forbes Middle East Top 100 Healthcare Leaders, reflecting his decades of leadership at Hikma, and the company’s ongoing impact on the healthcare industry.  Read more: https://lnkd.in/dRusTNUU #HikmaLeaders #GlobalHealthcare

#LookingBack2024. As a top three supplier of generic injectable medicines by volume in the US [1] with a growing portfolio of more than 160 products, we continue to make ongoing investments in our manufacturing facilities, expanding production lines, increasing our manufacturing capacity, ensuring patients have access to vital medicines. [1] IQVIA MAT May 2024, generic injectable volumes by eaches, excluding branded generics and Becton Dickinson  For more: https://www.hikma.com/ #Injectables #Hikma #US

#LookingBack2024. In April, #Hikma appoints Hafrun Fridriksdottir as President of our Generics business to strengthen our R&D pipeline, leverage our strong manufacturing capabilities and establish new business opportunities that will further build our position as one of the top providers of generic medicines in the US. Learn more about our leadership team: https://lnkd.in/dBpJWyf7 #Leadership #Generics #RD #Appointment